BCG vaccine immunity against human tuberculosis. The BCG vaccine can be anywhere from 0 to 80% effective in preventing tuberculosis for a duration of 15 years; however, its protective effect appears to vary according to geography and the lab in which the vaccine strain was grown. A number of different companies make BCG, sometimes using different genetic strains of the bacterium. This may result in different product characteristics. OncoTICE, used for bladder instillation for bladder cancer, was developed by Organon Laboratories (since acquired by Schering-Plough, and in turn acquired by Merck & Co.). Pacis BCG, made from the Montréal (Institut Armand-Frappier) strain,
Inoculation theory to back that idea up. There are also scholars on the other side who suggest that too much of a delay lessens the strengthening effect of inoculation. With this being said, it has been revealed that the effect of inoculation can still be significant weeks or even months after initial introduction or the treatment showing that it does produce somewhat long-lasting effects (Banas & Rains, 2010). Involvement is the final element of the inoculation process. Pfau, et al. (1997a) defined involvement as "the importance or salience of an attitude object for a receiver" and is “among the most important and